Shenzhen New Industries Biomedical (300832) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.069x

Based on the latest financial reports, Shenzhen New Industries Biomedical (300832) has a cash flow conversion efficiency ratio of 0.069x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥606.21 Million ≈ $88.71 Million USD) by net assets (CN¥8.74 Billion ≈ $1.28 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300832 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Shenzhen New Industries Biomedical - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Shenzhen New Industries Biomedical's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Shenzhen New Industries Biomedical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shenzhen New Industries Biomedical ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Bancolombia S.A
F:BXK
0.267x
Axos Financial Inc
NYSE:AX
0.042x
BRF S.A
F:P5Y
0.142x
Solaris Energy Infrastructure, Inc.
NYSE:SEI
0.072x
Yongxing Special Stainless Steel Co Ltd
SHE:002756
0.017x
Guangdong Electric Power Development Co Ltd
SHE:000539
0.059x
One Gas Inc
NYSE:OGS
0.050x
Crocs Inc
NASDAQ:CROX
-0.037x

Annual Cash Flow Conversion Efficiency for Shenzhen New Industries Biomedical (2012–2024)

The table below shows the annual cash flow conversion efficiency of Shenzhen New Industries Biomedical from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see 300832 market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥8.58 Billion
≈ $1.26 Billion
CN¥1.36 Billion
≈ $198.49 Million
0.158x -15.87%
2023-12-31 CN¥7.54 Billion
≈ $1.10 Billion
CN¥1.42 Billion
≈ $207.54 Million
0.188x +25.01%
2022-12-31 CN¥6.40 Billion
≈ $936.45 Million
CN¥962.39 Million
≈ $140.83 Million
0.150x +9.15%
2021-12-31 CN¥5.61 Billion
≈ $821.21 Million
CN¥773.22 Million
≈ $113.15 Million
0.138x -32.23%
2020-12-31 CN¥4.80 Billion
≈ $703.01 Million
CN¥976.65 Million
≈ $142.92 Million
0.203x -23.28%
2019-12-31 CN¥3.14 Billion
≈ $459.30 Million
CN¥831.73 Million
≈ $121.71 Million
0.265x -10.68%
2018-12-31 CN¥2.37 Billion
≈ $346.26 Million
CN¥701.97 Million
≈ $102.72 Million
0.297x +0.19%
2017-12-31 CN¥1.77 Billion
≈ $259.33 Million
CN¥524.73 Million
≈ $76.78 Million
0.296x -13.68%
2016-12-31 CN¥1.42 Billion
≈ $207.68 Million
CN¥486.81 Million
≈ $71.24 Million
0.343x +14.71%
2015-12-31 CN¥1.02 Billion
≈ $149.72 Million
CN¥305.93 Million
≈ $44.77 Million
0.299x -27.98%
2014-12-31 CN¥610.52 Million
≈ $89.34 Million
CN¥253.47 Million
≈ $37.09 Million
0.415x +13.70%
2013-12-31 CN¥378.84 Million
≈ $55.44 Million
CN¥138.33 Million
≈ $20.24 Million
0.365x +62.39%
2012-12-31 CN¥248.18 Million
≈ $36.32 Million
CN¥55.80 Million
≈ $8.17 Million
0.225x --

About Shenzhen New Industries Biomedical

SHE:300832 China Medical Devices
Market Cap
$4.83 Billion
CN¥33.00 Billion CNY
Market Cap Rank
#3706 Global
#560 in China
Share Price
CN¥42.00
Change (1 day)
-1.64%
52-Week Range
CN¥42.00 - CN¥70.18
All Time High
CN¥98.01
About

Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was found… Read more